Mesenchymal Stem Cell Potency Assay via TNF-α Stimulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current assays for assessing the potency of mesenchymal stem cells (MSCs) fail to accurately measure their ability to produce anti-inflammatory cytokines in response to pro-inflammatory cytokines, leading to inconsistent and unreliable potency assessments for therapeutic applications.

Innovation Solution

A method involving stimulation of MSCs with TNF-α followed by quantification of anti-inflammatory cytokine production, which includes specific combinations of pro-inflammatory cytokines like TNF-α and IL-17A, to assess their immunomodulatory capacity, using electrochemiluminescence immunoassays for sensitive detection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current assays are used to assess MSC potency, then the assessment process is simple, but the reliability and accuracy of potency measurement is poor

Engineering Contradiction:

Improvepotency assessment reliabilityVSAvoidassay complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by pre-stimulating MSCs with pro-inflammatory cytokines (TNF-α, IL-17A) before assessing their anti-inflammatory cytokine production capacity. This pre-treatment step ensures that the cells are in a physiologically relevant state that reflects their true therapeutic potency, thereby improving measurement reliability without excessive complexity

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses electrochemiluminescence immunoassays as an intermediary detection method to measure anti-inflammatory cytokine production. This intermediary technique provides highly sensitive and specific detection capabilities, enabling reliable potency assessment while maintaining manageable assay complexity through standardized detection protocols

Inventive Principle:

Principle #24Intermediary (Mediator)

2Measurement precision

If current assays are used to assess MSC potency, then the procedure is straightforward, but the measurement precision and consistency are poor

Engineering Contradiction:

Improvepotency measurement precisionVSAvoidassay procedure complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent changes key assay parameters by implementing specific stimulation conditions (TNF-α and IL-17A combinations) and measurement time points to optimize anti-inflammatory cytokine production detection. These parameter optimizations enable precise potency measurement while keeping the procedure manageable through standardized protocols

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs electrochemiluminescence immunoassays as an intermediary detection system that provides high measurement precision for anti-inflammatory cytokine quantification. This intermediary technique enables accurate and consistent potency measurements while maintaining procedural complexity at acceptable levels through standardized detection methods

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If MSC potency is assessed without pro-inflammatory stimulation, then the assay is simpler, but the results do not reflect true therapeutic capacity

Engineering Contradiction:

Improvetherapeutic capacity assessmentVSAvoidassay procedure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the harmful pro-inflammatory stimulation into a beneficial assessment tool by using controlled exposure to TNF-α and IL-17A to elicit and measure the MSCs' anti-inflammatory response. This approach transforms a potentially harmful stimulus into a valuable diagnostic tool for evaluating therapeutic capacity

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach increases the reliability and reduces variability in MSC potency assessments, ensuring the stability and consistency of cell-based therapeutic products by accurately measuring the production of anti-inflammatory cytokines, thereby improving the effectiveness of MSCs in treating inflammatory-related diseases.

Implementation Method 1

stimulating the MSCs with a pro-inflammatory cytokine or molecule... identifying and quantifying the levels of anti-inflammatory cytokine production

Methodology Applied

Scientific EffectCytokine signaling:

Implementation Method 2

using electrochemiluminescence immunoassays for sensitive detection

Methodology Applied

Scientific EffectElectrochemiluminescence: Electrochemiluminescence

Data Source

PatentUS20230221303A1Potency assay

Publication Date: 2023.07.13 LONGEVERON INC

AI summary

A method for assessing the potency of MSCs to produce anti-inflammatory cytokines in response to a pro-inflammatory stimulus. The method comprises stimulating the MSCs with one or more proinflammatory cytokines, such as TNF-α, for a duration of time and then identifying and quantifying the production of anti-inflammatory cytokines. MSCs that produce potent levels of anti-inflammatory cytokines in response to TNF-α can be used in treatments for aging-related conditions, including aging frailty and Alzheimer's disease, and can also be used to treat corona virus infections. The method shows that TNF-α induced MSCs robustly secrete several anti-inflammatory cytokines, including IL-1 receptor antagonist (IL-1RA), IL-10, and granulocyte colony stimulating factor (G-CSF).